Motiv8 Investments’s ARK Genomic Revolution ETF ARKG Stock Holding History

Motiv8 Investments’s Portfolio ARKG Stock Details ARKG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	$1	Buy	+50	New	+$1.5K	﹤0.01%	817

Other funds holding ARKG

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Motiv8 Investments's ARKG Position: Q4 2025 in Review

Motiv8 Investments opened a new position in ARK Genomic Revolution ETF (ARKG) in Q4 2025: 50 shares worth $1. The stake represents ﹤0.01% of the portfolio and ranks #817 among its holdings.

238 funds tracked by Wall St. Rank hold ARKG as of Q4 2025.

Motiv8 Investments held 50 shares of ARK Genomic Revolution ETF worth $1 as of Q4 2025.
ARK Genomic Revolution ETF was a new Motiv8 Investments position in Q4 2025.
ARK Genomic Revolution ETF made up ﹤0.01% of Motiv8 Investments's portfolio in Q4 2025, its #817 holding.
238 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q4 2025.

Based on Motiv8 Investments's 13F filing for Q4 2025, filed 13 Feb 2026.